Gilead's twice-yearly shot cut HIV infections by 96% in trial
The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
This website uses cookies to enhance your browsing experience. By continuing to use this site, you consent to the use of cookies. Please review our Privacy Policy for more information on how we handle your data.